Genmab A Quick Ratio (GMAB) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Genmab A  (NASDAQ: GMAB)

Genmab A's Quick Ratio

GMAB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 0.34 a new company low.

Within Major Pharmaceutical Preparations industry 121 other companies have achieved higher Quick Ratio than Genmab A in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from to 1378.

Explain Quick Ratio?
How much Cash & cash equivalents GMAB´s has?
What are GMAB´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GMAB Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q2
Y / Y Current Liabilities Change 660.96 % 697.85 % - 1611.23 % -60.62 %
Y / Y Cash & cash equivalent Change -80.47 % 175.72 % -90.72 % 7.56 % -2.75 %
Quick Ratio MRQ 0.34 0.34 - 0.34 13.36
GMAB's Total Ranking # 1378 # # # #
Seq. Current Liabilities Change -84.29 % - - 4742.77 % -83.53 %
Seq. Cash & cash equivalent Change -84.29 % 738.8 % -88.08 % 24.28 % 121.86 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 122
Healthcare Sector # 272
Overall Market # 1378


Quick Ratio Statistics
High Average Low
0.34 0.34 0.34
(Dec 31 2025)  




Financial Statements
Genmab A's Current Liabilities $ 786 Millions Visit GMAB's Balance sheet
Genmab A's Cash & cash equivalent $ 269 Millions Visit GMAB's Balance sheet
Source of GMAB's Sales Visit GMAB's Sales by Geography


Cumulative Genmab A's Quick Ratio

GMAB's Quick Ratio for the trailling 12 Months

GMAB Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 901.71 % 717.63 % 549.25 % 442.36 % 8.81 %
Y / Y Cash & cash equivalent TTM Growth -32.7 % -14.13 % -40.58 % 2.82 % 2.23 %
Quick Ratio TTM 0.36 0.5 0.68 1.02 5.39
Total Ranking TTM # 4545 # # # #
Seq. Current Liabilities TTM Growth 6.75 % 76.32 % -0.94 % 437.24 % -12.86 %
Seq. Cash & cash equivalent TTM Growth -22.15 % 27.87 % -33.77 % 2.08 % -0.67 %

Quick ratio ranking by company, industry and sector >> Back to GMAB Financial Strength Comparisons >> Go to Compare GMAB Quick Ratio to its Competitors

On the trailing twelve months basis Due to drop in Current Liabilities in the Q4 2025 to $785.83 millions, cumulative Quick Ratio decreased to 0.36 below the Genmab A average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 481 other companies have achieved higher Quick Ratio than Genmab A. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from to 4545.

Explain Quick Ratio?
How much Cash & cash equivalents GMAB´s has?
What are GMAB´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 482
Healthcare Sector # 987
Within the Market # 4545


trailing twelve months Quick Ratio Statistics
High Average Low
5.99 4.33 1.2
(Dec 31 2023)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Organogenesis Holdings Inc   0.94 $ 93.679  Millions$ 100.124  Millions
Abbott Laboratories  0.93 $ 8,939.000  Millions$ 9,587.000  Millions
Beyondspring Inc   0.93 $ 12.561  Millions$ 13.504  Millions
Tg Therapeutics Inc   0.92 $ 141.970  Millions$ 153.760  Millions
Prestige Consumer Healthcare Inc   0.92 $ 97.884  Millions$ 106.623  Millions
Nanobiotix S a   0.92 $ 59.080  Millions$ 64.408  Millions
Collegium Pharmaceutical Inc   0.91 $ 386.679  Millions$ 425.760  Millions
Ironwood Pharmaceuticals inc   0.89 $ 215.456  Millions$ 243.145  Millions
Medicus Pharma Ltd   0.88 $ 8.705  Millions$ 9.938  Millions
Serina Therapeutics Inc   0.86 $ 3.056  Millions$ 3.563  Millions
Nls Pharmaceutics Ltd  0.86 $ 4.402  Millions$ 5.139  Millions
Cormedix Inc   0.85 $ 157.330  Millions$ 184.012  Millions
Oncolytics Biotech Inc   0.85 $ 5.202  Millions$ 6.101  Millions
Axsome Therapeutics Inc   0.85 $ 322.933  Millions$ 378.836  Millions
Integrated Biopharma Inc  0.85 $ 3.615  Millions$ 4.248  Millions
Turn Therapeutics Inc   0.85 $ 5.085  Millions$ 6.003  Millions
Harrow Inc   0.76 $ 72.927  Millions$ 96.302  Millions
Lifevantage Corp  0.74 $ 20.201  Millions$ 27.217  Millions
Supernus Pharmaceuticals inc   0.73 $ 128.448  Millions$ 177.074  Millions
Evolus Inc   0.71 $ 53.826  Millions$ 75.305  Millions
Geron Corporation  0.71 $ 79.440  Millions$ 111.542  Millions
Karyopharm Therapeutics Inc   0.69 $ 63.744  Millions$ 92.060  Millions
Eton Pharmaceuticals Inc   0.67 $ 25.942  Millions$ 38.490  Millions
Pharming Group N v   0.66 $ 145.305  Millions$ 221.690  Millions
Rein Therapeutics Inc   0.65 $ 3.215  Millions$ 4.916  Millions
Journey Medical Corp  0.64 $ 24.090  Millions$ 37.442  Millions
Ionis Pharmaceuticals Inc   0.64 $ 372.260  Millions$ 579.151  Millions
Pfizer Inc  0.63 $ 23,454.000  Millions$ 36,984.000  Millions
Lakewood-Amedex Biotherapeutics Inc.  0.62 $ 0.236  Millions$ 0.381  Millions
Jazz Pharmaceuticals Plc  0.62 $ 1,391.899  Millions$ 2,246.721  Millions

Date modified: 2026-07-07T11:25:19+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.